Chinese Antibody Society

Antibody Therapeutics, official journal of Chinese Antibody Society, published by Oxford University Press, has been accepted by Clarivate for indexing in the Emerging Sources Citation Index (ESCI). This is another key milestone of the journal after inclusions by other leading databases such as PubMed and Scopus (2023 CiteScore: 8.7) Click the link to explore more author benefits through https://lnkd.in/eP9nFpMa We are also welcoming therapeutic antibody related submissions through https://lnkd.in/dMJjtiD

High-throughput screening has become an important approach for formulators to rapidly and robustly identify operational spaces for antibody therapeutics. This work describes a fully integrated high-throughput solution for high concentration trastuzumab biosimilar formulation screening using readily available instruments. The effort can help to accelerate the adoption of high-throughput methodologies in mAb formulation development. The authors of this new open access paper are from Catalent Pharma Solutions. The corresponding author is Dr. Jingtao Zhang, a Scientific Director at Catalent. This new paper (currently in accepted manuscript format) was published in Antibody Therapeutics which is the official journal of Chinese Antibody Society. Antibody Therapeutics is an international peer-reviewed, open access journal published by Oxford University Press, and is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal. https://lnkd.in/gsTu_U2 #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics

In addition to one of the most read papers we featured yesterday, we’d like to spotlight additional 4 most read articles published in Antibody Therapeutics (indexed by ESCI and Scopus, 2023 CiteScore: 8.7) in the past a couple of years. The 4th and last excellent article we'd like to feature is entitled “Structure and function of therapeutic antibodies approved by the US FDA in 2023”. The author provides structural insights into the 12 novel therapeutic antibodies approved by the US FDA in 2023. This paper was published in April this year, and has received 7,000+ views/downloads and 2 citations. The author of this paper is Dr. William Strohl who is a prestigious expert in therapeutic antibodies, and used to be a Vice President and Head of Janssen BioTherapeutics, ,and is currently running his own Bistro Biotech Consulting. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics #fadapproval #fda #fadapprovals

In addition to one of the most read papers we featured last weekend, we’d like to spotlight additional 4 most read articles published in Antibody Therapeutics (indexed by ESCI and Scopus, 2023 CiteScore: 8.7) in the past a couple of years. The 3rd excellent article we'd like to feature is entitled “Engineering antibody and protein therapeutics to cross the blood–brain barrier”. The authors of this excellent review article  summarized a comprehensive list of design tips to generate successful bispecific BBB (blood–brain barrier)-crossing antibodies. This paper was published in October, 2022, and has received 8,000+ views/downloads and 25 citations. The two co-corresponding authors are Dr. Zhao Peng, currently a Senior Scientist at AstraZeneca and Professor Zhiqiang An, the Vice President of Drug Discovery at The University of Texas Health Science Center at Houston (UTHealth Houston). #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics #bloodbrainbarrier #bbb

We have reached 15,000 followers on Linkedin! We appreciate everyone for your continuous attention and support in Chinese Antibody Society!

In addition to one of the most read papers we featured on October 12, we’d like to spotlight additional 4 most read articles published in Antibody Therapeutics (indexed by ESCI and Scopus, 2023 CiteScore: 8.7) in the past a couple of years. The 2nd excellent article we'd like to feature is entitled “Developability assessment at early-stage discovery to enable development of antibody-derived therapeutics”. This article reviews the assessment of developability at early-stage discovery of antibody-derived therapeutics, including monoclonal antibodies, bispecific antibodies and antibody drug conjugates, and suggests general considerations and practices to mitigate the risk of moving a suboptimal candidate to the development stage. The article also comprehensively reviews the physicochemical properties of an antibody candidate that could affect its key attributes of homogeneity, stability, solubility and specificity. In addition, the article summarizes experimental and in silico methods for the assessment of developability at the discovery stage. This excellent review article was published in January, 2023, and has received 20,000+ views/downloads and 24 citations. The corresponding author is Dr. George (Zhuozhi) Wang, a Vice President of Antibody Discovery at WuXi Biologics. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #biologics

In addition to one of the most read papers we featured yesterday, we’d like to spotlight additional 4 most read articles published in Antibody Therapeutics (indexed by ESCI and Scopus, 2023 CiteScore: 8.7) in the past a couple of years. The first one is entitled “Next generation of multispecific antibody engineering”.  The authors of this article from Gilead Sciences look at promising protein building blocks that can be used to assemble multispecifics, discuss advancements in computational protein design that have been used to overcome challenges, and what it will take to enable rapid and reliable multispecific design via machine learning. This article was published in January this year, and has been viewed/downloaded 11,000+ times, and has received 8 citations. The corresponding author of this excellent paper is Dr. Fernando Garces who is currently the CEO of BioGlyph. #antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery  #biologics

Presumably associated with this year’s Nobel Prize in Chemistry regarding AI & protein/antibody, although this paper was published just in this month in Antibody Therapeutics, it already quickly becomes one of the most read papers. The authors of this new open access article from Just - Evotec Biologics describe a novel, cost-effective and accelerated approach to therapeutic antibody discovery, that couples de novo human antibodies derived in silico with high throughput screening technologies. Just-Evotec Biologics’ platform’s applicability is demonstrated here by the identification of a panel of humanoid antibodies that are effective and with high developability potential. The first and corresponding author is Cristina Moldovan Loomis, Ph.D.. #antibodies #antibody #antibodytherapeutics #mabs #mab #biologics #Artificialintelligence #ai

FDA signed off on Pfizer's Hympavzi (marstacimab-hncq), an anti-tissue factor pathway inhibitor for patients age 12 and older with hemophilia A or B who have not developed antibodies to previous inhibitor treatments. Hympavzi is a once-weekly subcutaneous injection that helps limit the bleeding episodes that accompany the blood-clotting disorder. It is the first U.S.-approved treatment for hemophilia to be administered by a user-friendly, pre-filled auto-injector pen. https://lnkd.in/eDJVwE89

ONO PHARMACEUTICAL CO., LTD. today announced that it has entered into a license agreement with LigaChem Biosciences, Inc. (LCB) for LCB97, a preclinical stage #ADC aimed at being a first-in-class drug in the field of solid tumors, as well as a research collaboration and license agreement to generate novel ADC candidates by leveraging LCB’s proprietary ConjuAll™ ADC platform.LCB97 is an ADC generated and developed by leveraging LCB’s proprietary ConjuAll™ ADC platform, targeting at L1 cell adhesion molecule (L1CAM) which has been reported to be highly expressed in multiple solid tumors. Under this Agreement, Ono will make an upfront payment to LCB, along with milestone payments based on research and development progress and sales, up to a maximum of 700 million US dollars, as well as tiered royalties based on net sales. https://lnkd.in/eEu4b4Ev